IGHE and asthma: Quilizumab reduced total-serum and allergen-specific IgE levels by 30%–40%, but had no impact on asthma exacerbations, lung function, or symptoms in an RCT on 578 patients with allergic asthma that could not be controlled by high-dose ICS (Harris et al., 2016).